Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec

Background. In Canada, the current recommendation is to offer PPV23 to adults ≥ 65 years. PCV13 is now licensed for adults. Methods. Invasive pneumococcal disease (IPD) cases in adults 65–74 years of age in the Quebec notifiable diseases registry were classified into five serotype categories. Poisso...

Full description

Saved in:
Bibliographic Details
Main Authors: Z. Zhou, G. Deceuninck, B. Lefebvre, P. De Wals
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2017/4347206
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561154405171200
author Z. Zhou
G. Deceuninck
B. Lefebvre
P. De Wals
author_facet Z. Zhou
G. Deceuninck
B. Lefebvre
P. De Wals
author_sort Z. Zhou
collection DOAJ
description Background. In Canada, the current recommendation is to offer PPV23 to adults ≥ 65 years. PCV13 is now licensed for adults. Methods. Invasive pneumococcal disease (IPD) cases in adults 65–74 years of age in the Quebec notifiable diseases registry were classified into five serotype categories. Poisson regression models were fitted to monthly rates observed in 2000–2014 and predictions were made for 2015–2024, using theoretical assumptions regarding indirect effects of childhood vaccination and serotype replacement. Results. IPD rates caused by PCV7 serotypes decreased markedly since PCV7 introduction for children in December 2004. This trend is also underway for additional PCV13 serotypes except serotype 3. Additional PPV23 serotypes and nonvaccine serotypes have been on rise since 2004 and this is expected to continue. A small decrease in overall IPD incidence in the next decade is predicted. The proportion of PCV13 serotypes represented 33% of IPD cases in 2014 and would be 20% (95% CI: 15% to 28%) in 2024. PPV23 coverage was 53% in 2014 and is expected to be 47% (95% CI: 26% to 85%) in 2024. Conclusion. The potential usefulness of a combined PCV13 + PPV23 program for elderly adults would decrease over time but PCV13 would be the only option to prevent serotype 3 IPD.
format Article
id doaj-art-7e0736c7582647aca06e6628c261a876
institution Kabale University
issn 1712-9532
1918-1493
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases and Medical Microbiology
spelling doaj-art-7e0736c7582647aca06e6628c261a8762025-02-03T01:25:44ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95321918-14932017-01-01201710.1155/2017/43472064347206Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in QuebecZ. Zhou0G. Deceuninck1B. Lefebvre2P. De Wals3Quebec University Hospital Research Center, Quebec City, QC, CanadaQuebec University Hospital Research Center, Quebec City, QC, CanadaLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC, CanadaQuebec University Hospital Research Center, Quebec City, QC, CanadaBackground. In Canada, the current recommendation is to offer PPV23 to adults ≥ 65 years. PCV13 is now licensed for adults. Methods. Invasive pneumococcal disease (IPD) cases in adults 65–74 years of age in the Quebec notifiable diseases registry were classified into five serotype categories. Poisson regression models were fitted to monthly rates observed in 2000–2014 and predictions were made for 2015–2024, using theoretical assumptions regarding indirect effects of childhood vaccination and serotype replacement. Results. IPD rates caused by PCV7 serotypes decreased markedly since PCV7 introduction for children in December 2004. This trend is also underway for additional PCV13 serotypes except serotype 3. Additional PPV23 serotypes and nonvaccine serotypes have been on rise since 2004 and this is expected to continue. A small decrease in overall IPD incidence in the next decade is predicted. The proportion of PCV13 serotypes represented 33% of IPD cases in 2014 and would be 20% (95% CI: 15% to 28%) in 2024. PPV23 coverage was 53% in 2014 and is expected to be 47% (95% CI: 26% to 85%) in 2024. Conclusion. The potential usefulness of a combined PCV13 + PPV23 program for elderly adults would decrease over time but PCV13 would be the only option to prevent serotype 3 IPD.http://dx.doi.org/10.1155/2017/4347206
spellingShingle Z. Zhou
G. Deceuninck
B. Lefebvre
P. De Wals
Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec
Canadian Journal of Infectious Diseases and Medical Microbiology
title Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec
title_full Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec
title_fullStr Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec
title_full_unstemmed Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec
title_short Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec
title_sort forecasting trends in invasive pneumococcal disease among elderly adults in quebec
url http://dx.doi.org/10.1155/2017/4347206
work_keys_str_mv AT zzhou forecastingtrendsininvasivepneumococcaldiseaseamongelderlyadultsinquebec
AT gdeceuninck forecastingtrendsininvasivepneumococcaldiseaseamongelderlyadultsinquebec
AT blefebvre forecastingtrendsininvasivepneumococcaldiseaseamongelderlyadultsinquebec
AT pdewals forecastingtrendsininvasivepneumococcaldiseaseamongelderlyadultsinquebec